chevron_leftBack
As of 24 April 2025, BerGenBio ASA has a market cap of $6.83M USD, ranking #34700 globally and #232 in Norway. It ranks #3479 in the Healthcare sector, and #1157 in the Biotechnology industry.
Key Stats
Market Cap
$6.83MUSD
71.06M NOK
Enterprise Value
-$6.48MUSD
-68.28M NOK
Revenue (TTM)
$81.5KUSD
848.0K NOK
EBITDA (TTM)
-$14.32MUSD
-150.78M NOK
Net Income (TTM)
-$13.39MUSD
-139.28M NOK
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Olav Hellebo
open_in_new
Employees
15
Founded
2007
Website
bergenbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.2% | 5.4% | 9.9% | -79% | -79% | -89% |
Upcoming Earnings
Earnings Date
Tue, Apr 29
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BGBIO
ISIN: NO0013251173
Shares Out.:
Shares Outstanding:
39.087M1
Shares Float:
25.471M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.76 NOK |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About BerGenBio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
